- Advertise
- Contact Us
- Contribute
- Editorial Info
- Terms and Conditions
- Privacy Policy
- Do Not Sell My Personal Information
- About Us
© 2023 MJH Life Sciences™ and Endocrinology Network. All rights reserved.
Women's Health
The Endocrinology Network® Women’s Health clinical resource center is a hub of news and information related to health of women at all ages and stages of life. This page offers perspective and insight on the latest information from multiple fields of women’s health, including gestational diabetes, hormone therapy, menopause management, and reproductive health.
USPSTF Reaffirms Recommendations Against Hormone Therapy for Primary Prevention in Postmenopausal Persons
November 01, 2022
Published on November 1, the USPSTF reaffirmed their stance against use of hormone therapy for primary prevention of chronic conditions in postmenopausal persons, which was the stance the organization took in their 2017 recommendations.
Preconception Thyroid Function Can Predict Delayed Time to Pregnancy, Risk of Spontaneous Abortion
September 02, 2022
An analysis of more than 11 million women in China details associations between preconception thyroid dysfunction, measured as thyrotropin levels, and delayed time to pregnancy and risk of spontaneous abortion.
No Difference in Outcomes with Lower Glycemic Threshold for Diagnosing Gestational Diabetes
August 19, 2022
Despite increasing the rate of diagnoses and healthcare utilization, the GEMS study found a lower glycemic criterion for diagnosis of gestational diabetes was not associated with a reduced risk of negative outcomes for mother and offspring.
MYFEMBREE Scores FDA Approval for Endometriosis Pain
August 06, 2022
On August 5, Pfizer announced the FDA's approval of relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg (MYFEMBREE) for the management of moderate to severe pain associated with endometriosis in premenopausal women for up to 24 months.
Women's Preventive Services Initiative Releases Guidance for Preventing Obesity in Midlife
August 04, 2022
A national coalition of more than 20 health professional organizations and patient representatives, the WPSI recommendation for preventing obesity in midlife women advocates for counseling to maintain weight or limit weight gain among women with normal or overweight BMI aged 40-60 years.
Endocrine Month in Review: July 2022
July 30, 2022
Our endocrinology month in review spotlights the most popular content from the past month. The top content from July includes hormone therapy guidance from NAMS, a comparison of management practices among Medicare beneficiaries, and a recap of the top approvals from the first half of 2022.
Endometriosis Linked to 34% Increase in Stroke Risk
July 21, 2022
Women with endometriosis had a 34% greater risk of stroke than women without the chronic inflammatory gynecological condition, according to an analysis of the Nurses Health Study II.
Hormone Replacement Therapy Does Not Increase Breast Cancer Recurrence, Mortality in Survivors
July 20, 2022
An analysis of data from more than 8400 postmenopausal women with a history of early-stage nonmetastatic, ER-positive breast cancer suggests there was no increase in risk of breast cancer recurrence or mortality observed with use of vaginal estrogen therapy or menopausal hormone therapy.
North American Menopause Society Updates Hormone Therapy Guidance
July 08, 2022
Released on July 7, the 2022 hormone therapy position statement from the North American Menopause Society is 28 pages in length and has received endorsement from 20 international organizations, including the AACE.
Increased PFAS Exposure Linked to High Blood Pressure in Aging Women
June 18, 2022
According to a new study, cumulative exposure to PFAS during midlife can increase the risk of incident hypertension among women as they age, with those in the highest tertile of cumulative exposure at a 71% greater risk of developing hypertension.